Bunavail

Pain, Itching, Septic Shock + 7 more

Treatment

8 FDA approvals

20 Active Studies for Bunavail

What is Bunavail

Naloxone

The Generic name of this drug

Treatment Summary

Naloxone is a medication that blocks or reverses the effects of opioid drugs. It is used to treat drug overdoses caused by opioids such as morphine, hydromorphone, methadone, heroin, and fentanyl. It works by binding to opioid receptors in the body and blocking the effects of other drugs bound to those receptors. Common symptoms of an opioid overdose include trouble breathing, slow heart rate, slurred speech, drowsiness, and constricted pupils. If not treated, this can lead to vomiting, no pulse or breathing, loss of consciousness and even death. Naloxone can be given by intram

Narcan

is the brand name

image of different drug pills on a surface

Bunavail Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Narcan

Naloxone

1971

241

Approved as Treatment by the FDA

Naloxone, otherwise called Narcan, is approved by the FDA for 8 uses including Pain and Opioid Dependence .

Pain

Used to treat moderate Pain in combination with Pentazocine

Opioid Dependence

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Pain

Used to treat Severe Pain in combination with Pentazocine

Opioid-Related Disorders

Used to treat Opioid Dependence in combination with Buprenorphine

Septic Shock

Opioids

Respiratory Insufficiency

Effectiveness

How Bunavail Affects Patients

Naloxone is a medication that is used to reverse the effects of an opioid overdose. It works quickly but may need to be taken multiple times. It is safe to take even if the person has not taken opioids, but they may experience withdrawal symptoms. It is important to note that naloxone may not completely fix all symptoms if the person has also taken other drugs.

How Bunavail works in the body

Naloxone is a drug that blocks the effects of opioids in the body. It binds to the opioid receptors, preventing opioids from binding and blocking their effects. If someone has not taken opioids, naloxone will not have any effect.

When to interrupt dosage

The advised measure of Bunavail is dependent upon the determined condition, including Opioid Dependence, Pain and Septic Shock. The dosage differs, depending on the technique of delivery (e.g. Spray, metered or Tablet) specified in the table below.

Condition

Dosage

Administration

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Itching

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioid-Related Disorders

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Septic Shock

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Respiratory Insufficiency

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Emergency Care

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Opioids

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Pain

, 0.4 mg/mL, 1.0 mg/mL, 0.5 mg, 2.0 mg, 0.4 mg, 40.0 mg/mL, 4.0 mg, 20.0 mg/mL, 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg, 1.0 mg, 3.0 mg, 2.9 mg, 0.36 mg, 0.71 mg, 1.4 mg, 2.1 mg, 0.18 mg, 0.7 mg, 0.3 mg, 4.0 mg/mL, 0.02 mg/mL, 1.8 mg, 80.0 mg/mL, 50.0 mg/mL

, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection - Parenteral, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Oral, Tablet, Tablet - Oral, Sublingual, Tablet - Sublingual, Film, soluble, Film, soluble - Sublingual, Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution - Intramuscular; Intravenous; Subcutaneous, Solution, Nasal, Spray, Spray - Nasal, Tablet, extended release, Tablet, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Spray, metered, Spray, metered - Nasal, Film, Film - Buccal, Buccal, Pill - Sublingual, Pill, Buccal; Sublingual, Film, soluble - Buccal; Sublingual, Film - Buccal; Sublingual, Intravenous, Injection - Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Parenteral; Topical, Inhalant, Inhalant - Nasal

Warnings

Bunavail has one contraindication, so it should not be used when someone experiences any of the conditions listed in the table below.

Bunavail Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Naloxone may interact with Pulse Frequency

There are 20 known major drug interactions with Bunavail.

Common Bunavail Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Naloxone.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Naloxone.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Naloxone.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Naloxone.

Bunavail Toxicity & Overdose Risk

If a patient hasn't taken opioids, naloxone won't have much of an effect. The toxic dose of naloxone in mice is higher than 1g/kg when taken orally, 80mg/kg when given through the abdomen, and 286mg/kg when given through the skin. The toxic dose in rats is higher than 1g/kg when taken orally, 239mg/kg when given through the abdomen, and 500mg/kg when given through the skin.

image of a doctor in a lab doing drug, clinical research

Bunavail Novel Uses: Which Conditions Have a Clinical Trial Featuring Bunavail?

64 active trials are being conducted to investigate Bunavail's potential as a therapeutic agent for Opioids, Opioids-Induced Pain and other associated conditions.

Condition

Clinical Trials

Trial Phases

Emergency Care

0 Actively Recruiting

Opioids

0 Actively Recruiting

Opioid-Related Disorders

0 Actively Recruiting

Septic Shock

0 Actively Recruiting

Respiratory Insufficiency

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Pain

0 Actively Recruiting

Opioids

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1

Opioids

6 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Pain

0 Actively Recruiting

Bunavail Reviews: What are patients saying about Bunavail?

5

Patient Review

2/23/2015

Bunavail for Narcotic Addiction

I've been addicted to pills and heroin for over a decade, and this is by far the best treatment I've tried. Methadone and suboxone didn't work as well for me, and I find that this treatment doesn't have any horrible after taste or cravings. I'm also using half the amount of suboxone, which is great.

5

Patient Review

12/20/2016

Bunavail for Narcotic Addiction

I found that this drug absorbed quicker than Suboxone and required less mg to be effective. From reading the negative reviews, it's obvious that these people either didn't give it a chance or aren't actually trying to get better. Bunavail works great for me.

5

Patient Review

10/30/2015

Bunavail for Chronic Pain

Super easy to use and really quick-acting.

3

Patient Review

2/26/2015

Bunavail for Narcotic Addiction

I wasn't as impressed with this drug as I was with suboxone. It takes a while to work- sometimes up to 45 minutes- and even then I still have to spit it out. Suboxone just seems to do a better job at managing cravings and pain.

2.7

Patient Review

12/29/2014

Bunavail for Narcotic Addiction

I'm not sure if this drug is effective yet. I took it today for the first time and now I have a headache and feel jittery. I don't want to get addicted to another medication, so I'm going to talk to my doctor about it tomorrow.

2

Patient Review

4/2/2016

Bunavail for Narcotic Addiction

This product isn't as effective as other bupe products I've tried. It's also bulky and takes a while to dissolve, which makes it less convenient than it could be.

1.7

Patient Review

2/12/2017

Bunavail for Prevention of Opiate Drug Abuse

I have been taking Suboxone for a while, and I was doing well. But then I had to switch to Bunavail, which is not as effective. It wears off quickly and always makes me feel like I'm going through withdrawal.

1.7

Patient Review

5/26/2015

Bunavail for Narcotic Addiction

This didn't work for me at all. I feel like it took forever to dissolve, and when it finally did, it didn't seem to help at all. My doctor switched me off of this after just a few years; I'll be going back to the old medication next visit.

1

Patient Review

8/23/2015

Bunavail for Narcotic Addiction

I would not recommend this treatment to anyone. I only tried it because it was free, and I much prefer suboxone over it. It's my third time trying to come off of opioids, and this just doesn't work as well in my opinion.

1

Patient Review

10/8/2015

Bunavail for Narcotic Addiction

This is a terrible drug. Do not take it. It did nothing to help me with my withdrawal symptoms and made them worse.

1

Patient Review

12/21/2014

Bunavail for Narcotic Addiction

I'm in total agreement with the last person who reviewed this. It takes forever and there's still some left over. Not to mention, I don't think it works well at all since it doesn't seem to be properly absorbed into my cheek.

1

Patient Review

4/28/2017

Bunavail for Prevention of Opiate Drug Abuse

This medication was a terrible experience. I didn't sleep for four days, had difficulty urinating, it took too long to dissolve, and left chunks in my mouth. On the fifth day, I started vomiting and having debilitating upper stomach pain. The doctor prescribed suboxone instead and it's much more effective without all the horrendous side effects. So grateful for suboxone!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bunavail

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Bunavail the same as Suboxone?

"The main differences between Bunavail and Suboxone are: -Bunavail is more easily and completely absorbed into the bloodstream. -Suboxone is considered to be approximately twice as strong as Bunavail."

Answered by AI

What is Bunavail buccal film?

"BUNAVAIL is a yellow, rectangular film that is citrus-flavored and is intended to be applied to the buccal mucosa. The film has ink markings on the mucoadhesive side."

Answered by AI

What is Bunavail used for?

"Naloxone blocks the effects of opioids at the opioid receptors, and reverses the respiratory depression caused by buprenorphine.

This medication is a combination of buprenorphine and naloxone, and is used to treat opioid dependence or addiction. Buprenorphine is a drug that belongs to a class of mixed opioid agonist-antagonists, and helps to prevent withdrawal symptoms that can occur when other opioids are stopped. Naloxone is a drug that blocks the effects of opioids at the opioid receptors, and also reverses the respiratory depression that buprenorphine can cause."

Answered by AI

Is Bunavail still available?

"BioDelivery Sciences International, Inc. is discontinuing its drug Bunavail in the United States as of March 2020."

Answered by AI

Clinical Trials for Bunavail

Image of Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia in Vancouver, Canada.

Educational Interventions for Opioid Use in Dentistry

Any Age
All Sexes
Vancouver, Canada

The aim of this study is to estimate the impact of providing personalized prescribing data and educational materials on opioid prescribing to dentists in British Columbia, Canada. The main research questions are: 1. What is the impact of an intervention on the use of opioids for dental pain? The intervention includes a personalized prescribing report (a "Portrait"), brief educational summary, and patient education materials; and 2. Does the impact of the intervention increase when dentists are also invited to attend facilitated audit-and-feedback group sessions and to develop a practice improvement plan? Using administrative health data, the prescribing of those in different combinations of materials in the Early Group will be compared to those in the Delayed Group to estimate the impact of the materials on prescribing by the dentists.

Waitlist Available
Has No Placebo

Therapeutics Initiative - Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia

Colin Dormuth, ScD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Bunavail clinical trials?

We made a collection of clinical trials featuring Bunavail, we think they might fit your search criteria.
Go to Trials
Image of Toronto General Hospital in Toronto, Canada.

Transcutaneous Electrical Stimulation for Slow Breathing

18+
All Sexes
Toronto, Canada

After surgery, patients often recover in a special area called the Post Anesthesia Care Unit (PACU). Patients may receive pain medications either during the surgery or afterward in the PACU. While these medications are important for controlling pain, some of them can slow down breathing. To ensure patients' breathing remains safe, the nurses in the PACU monitor respiratory rate (how many breaths a patient takes per minute) and oxygen levels using standard monitoring equipment. This is the usual way they check for breathing concerns. If these monitors show that a patient's breathing has slowed down too much, nurses may wake the patient up or stimulate them using their voice or gentle physical touch to encourage deeper breaths. What is this study about? This research is testing a new approach that uses an additional monitor called capnography. Capnography helps detect slowing or stopping of breathing by measuring the carbon dioxide (CO2) exhaled by patients. If the monitor shows slowed or stopped breathing (called apnea, lasting at least 10 seconds), this study will test using a technology called transcutaneous electrical stimulation (TES) to encourage normal breathing. How does TES work? TES provides a slight, annoying sensation on the patient's skin-enough to wake them up without causing pain. This has been used in other studies to safely restore breathing after surgery. In this study, the researchers are testing whether a new automated device can deliver TES when the capnography monitor detects breathing issues. The goal is to test the feasibility (can this system work in the PACU?) and acceptability (how do patients feel about this approach?) of this technology. Who can join this study? Adults aged 18 or older who received general anesthesia and medications (opioids) for pain control during or after surgery are eligible. Patients recovering from surgery in the PACU at Toronto General Hospital may be invited to participate. Why is this study important? The study aims to reduce the risk of opioid-related breathing problems after surgery, making recovery safer and more comfortable for patients.

Recruiting
Has No Placebo

Toronto General Hospital

Have you considered Bunavail clinical trials?

We made a collection of clinical trials featuring Bunavail, we think they might fit your search criteria.
Go to Trials
Image of Pennsylvania Psychiatric Institute in Harrisburg, United States.

Semaglutide for Opioid Addiction

18 - 75
All Sexes
Harrisburg, PA

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Phase 2
Recruiting

Pennsylvania Psychiatric Institute (+2 Sites)

Jennifer Nyland, PhD

Have you considered Bunavail clinical trials?

We made a collection of clinical trials featuring Bunavail, we think they might fit your search criteria.
Go to Trials